Andrew A. Somogyi - Publications

Affiliations: 
University of Adelaide, Adelaide, South Australia, Australia 
Area:
Clinical Pharmacology, Pharmacogenomics, Pharmacokinetics, Pharmacy

131 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Thomas JHL, Lui L, Abell A, Tieu W, Somogyi AA, Bajic JE, Hutchinson MR. Toll-Like Receptors change morphine-induced antinociception, tolerance and dependence: studies using male and female TLR and Signalling gene KO mice. Brain, Behavior, and Immunity. PMID 35131445 DOI: 10.1016/j.bbi.2022.02.001  0.773
2018 Rowsell L, Wong KKH, Yee BJ, Eckert DJ, Somogyi AA, Duffin J, Grunstein RR, Wang D. The effect of acute morphine on obstructive sleep apnoea: a randomised double-blind placebo-controlled crossover trial. Thorax. PMID 30166422 DOI: 10.1136/Thoraxjnl-2018-211675  0.31
2018 Zheng Z, Gibson S, Helme RD, Wang Y, Lu DS, Arnold C, Hogg M, Somogyi AA, Da Costa C, Xue CCL. Effects of Electroacupuncture on Opioid Consumption in Patients with Chronic Musculoskeletal Pain: A Multicenter Randomized Controlled Trial. Pain Medicine (Malden, Mass.). PMID 29893942 DOI: 10.1093/pm/pny113  0.353
2018 Athanasos P, Ling W, Bochner F, White JM, Somogyi AA. Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose. Pain Medicine (Malden, Mass.). PMID 29514333 DOI: 10.1093/pm/pny025  0.399
2017 Currow D, Watts GJ, Johnson M, McDonald CF, Miners JO, Somogyi AA, Denehy L, McCaffrey N, Eckert DJ, McCloud P, Louw S, Lam L, Greene A, Fazekas B, Clark KC, et al. A pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness: Breathlessness, Exertion And Morphine Sulfate (BEAMS) study protocol. Bmj Open. 7: e018100. PMID 28716797 DOI: 10.1136/bmjopen-2017-018100  0.304
2017 Newcombe DAL, Somogyi AA, Bochner F, White JM. Impaired Psychomotor Function and Plasma Methadone and Levo-Alpha-Acetylmethadol (LAAM) Concentrations in Opioid-Substitution Patients. Experimental and Clinical Psychopharmacology. PMID 28414496 DOI: 10.1037/pha0000114  0.366
2017 Barratt DT, Somogyi AA. Role of pharmacogenetics in personalised imatinib dosing Translational Cancer Research. 6. DOI: 10.21037/16228  0.306
2017 Somogyi A, Barratt D, Tan E, Sia A. Innate Immune Genetic Markers Predict Postoperative Morphine Consumption in an Ethnicity-Dependent Manner Clinical Therapeutics. 39: e14. DOI: 10.1016/J.CLINTHERA.2017.05.044  0.339
2016 Somogyi AA, Sia AT, Tan EC, Coller JK, Hutchinson MR, Barratt DT. Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain. Pain. PMID 27649267 DOI: 10.1097/j.pain.0000000000000661  0.731
2015 Barratt DT, Klepstad P, Dale O, Kaasa S, Somogyi AA. Innate Immune Signalling Genetics of Pain, Cognitive Dysfunction and Sickness Symptoms in Cancer Pain Patients Treated with Transdermal Fentanyl. Plos One. 10: e0137179. PMID 26332828 DOI: 10.1371/journal.pone.0137179  0.346
2015 Currow DC, Quinn S, Ekstrom M, Kaasa S, Johnson MJ, Somogyi AA, Klepstad P. Can variability in the effect of opioids on refractory breathlessness be explained by genetic factors? Bmj Open. 5: e006818. PMID 25948405 DOI: 10.1136/bmjopen-2014-006818  0.397
2015 Li Y, Jackson KA, Slon B, Hardy JR, Franco M, William L, Poon P, Coller JK, Hutchinson MR, Currow DC, Somogyi AA. CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. British Journal of Clinical Pharmacology. PMID 25702819 DOI: 10.1111/bcp.12614  0.713
2015 Somogyi AA, Coller JK, Barratt DT. Pharmacogenetics of opioid response. Clinical Pharmacology and Therapeutics. 97: 125-7. PMID 25670515 DOI: 10.1002/cpt.23  0.388
2015 Corrigan F, Wu Y, Tuke J, Coller JK, Rice KC, Diener KR, Hayball JD, Watkins LR, Somogyi AA, Hutchinson MR. Alcohol-induced sedation and synergistic interactions between alcohol and morphine: a key mechanistic role for Toll-like receptors and MyD88-dependent signaling. Brain, Behavior, and Immunity. 45: 245-52. PMID 25542736 DOI: 10.1016/J.Bbi.2014.12.019  0.754
2014 Somogyi AA, Barratt DT, Ali RL, Coller JK. Pharmacogenomics of methadone maintenance treatment. Pharmacogenomics. 15: 1007-27. PMID 24956254 DOI: 10.2217/pgs.14.56  0.376
2014 Dooney NM, Sundararajan K, Ramkumar T, Somogyi AA, Upton RN, Ong J, O'Connor SN, Chapman MJ, Ludbrook GL. Pharmacokinetics of tramadol after subcutaneous administration in a critically ill population and in a healthy cohort. Bmc Anesthesiology. 14: 33. PMID 24914400 DOI: 10.1186/1471-2253-14-33  0.312
2014 Mulholland CV, Somogyi AA, Barratt DT, Coller JK, Hutchinson MR, Jacobson GM, Cursons RT, Sleigh JW. Association of innate immune single-nucleotide polymorphisms with the electroencephalogram during desflurane general anaesthesia. Journal of Molecular Neuroscience : Mn. 52: 497-506. PMID 24352713 DOI: 10.1007/s12031-013-0201-7  0.688
2013 Li Y, Coller JK, Hutchinson MR, Klein K, Zanger UM, Stanley NJ, Abell AD, Somogyi AA. The CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitro. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 1264-72. PMID 23550066 DOI: 10.1124/Dmd.113.051631  0.684
2013 Wang D, Somogyi AA, Yee BJ, Wong KK, Kaur J, Wrigley PJ, Grunstein RR. The effects of a single mild dose of morphine on chemoreflexes and breathing in obstructive sleep apnea. Respiratory Physiology & Neurobiology. 185: 526-32. PMID 23207373 DOI: 10.1016/j.resp.2012.11.014  0.366
2013 Maddison J, Somogyi AA, Jensen BP, James HM, Gentgall M, Rolan PE. The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype. British Journal of Clinical Pharmacology. 75: 208-16. PMID 22616655 DOI: 10.1111/J.1365-2125.2012.04335.X  0.583
2012 Barratt DT, Coller JK, Hallinan R, Byrne A, White JM, Foster DJ, Somogyi AA. ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmacogenomics and Personalized Medicine. 5: 53-62. PMID 23226062 DOI: 10.2147/PGPM.S29272  0.312
2012 Xue CC, Helme RD, Gibson S, Hogg M, Arnold C, Somogyi AA, Da Costa C, Wang Y, Lu SC, Zheng Z. Effect of electroacupuncture on opioid consumption in patients with chronic musculoskeletal pain: protocol of a randomised controlled trial. Trials. 13: 169. PMID 22978476 DOI: 10.1186/1745-6215-13-169  0.348
2012 Hutchinson MR, Northcutt AL, Hiranita T, Wang X, Lewis SS, Thomas J, van Steeg K, Kopajtic TA, Loram LC, Sfregola C, Galer E, Miles NE, Bland ST, Amat J, Rozeske RR, ... ... Somogyi AA, et al. Opioid activation of toll-like receptor 4 contributes to drug reinforcement. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 11187-200. PMID 22895704 DOI: 10.1523/Jneurosci.0684-12.2012  0.767
2012 Wang X, Loram LC, Ramos K, de Jesus AJ, Thomas J, Cheng K, Reddy A, Somogyi AA, Hutchinson MR, Watkins LR, Yin H. Morphine activates neuroinflammation in a manner parallel to endotoxin. Proceedings of the National Academy of Sciences of the United States of America. 109: 6325-30. PMID 22474354 DOI: 10.1073/Pnas.1200130109  0.796
2012 Coller JK, Michalakas JR, James HM, Farquharson AL, Colvill J, White JM, Somogyi AA. Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients. British Journal of Clinical Pharmacology. 74: 835-41. PMID 22369095 DOI: 10.1111/j.1365-2125.2012.04256.x  0.35
2012 Gelston EA, Coller JK, Lopatko OV, James HM, Schmidt H, White JM, Somogyi AA. Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. British Journal of Clinical Pharmacology. 73: 786-94. PMID 22092298 DOI: 10.1111/j.1365-2125.2011.04145.x  0.4
2012 Wu Y, Lousberg EL, Moldenhauer LM, Hayball JD, Coller JK, Rice KC, Watkins LR, Somogyi AA, Hutchinson MR. Inhibiting the TLR4-MyD88 signalling cascade by genetic or pharmacological strategies reduces acute alcohol-induced sedation and motor impairment in mice. British Journal of Pharmacology. 165: 1319-29. PMID 21955045 DOI: 10.1111/J.1476-5381.2011.01572.X  0.74
2012 Savvas SM, Somogyi AA, White JM. The effect of methadone on emotional reactivity. Addiction (Abingdon, England). 107: 388-92. PMID 21883603 DOI: 10.1111/j.1360-0443.2011.03634.x  0.317
2012 Coller J, Hutchinson M, Tuke J, White J, Somogyi A. 65. Association between immune genetic markers and opioid dependence Brain Behavior and Immunity. 26. DOI: 10.1016/J.Bbi.2012.07.089  0.728
2011 Huxtable CA, Roberts LJ, Somogyi AA, MacIntyre PE. Acute pain management in opioid-tolerant patients: a growing challenge. Anaesthesia and Intensive Care. 39: 804-23. PMID 21970125 DOI: 10.1177/0310057X1103900505  0.395
2011 Coller JK, Cahill S, Edmonds C, Farquharson AL, Longo M, Minniti R, Sullivan T, Somogyi AA, White JM. OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. Pharmacogenetics and Genomics. 21: 902-5. PMID 21946895 DOI: 10.1097/FPC.0b013e32834c5445  0.308
2011 Liu L, Coller JK, Watkins LR, Somogyi AA, Hutchinson MR. Naloxone-precipitated morphine withdrawal behavior and brain IL-1β expression: comparison of different mouse strains. Brain, Behavior, and Immunity. 25: 1223-32. PMID 21447380 DOI: 10.1016/j.bbi.2011.03.016  0.756
2011 Wu Y, Lousberg EL, Moldenhauer LM, Hayball JD, Robertson SA, Coller JK, Watkins LR, Somogyi AA, Hutchinson MR. Attenuation of microglial and IL-1 signaling protects mice from acute alcohol-induced sedation and/or motor impairment. Brain, Behavior, and Immunity. 25: S155-64. PMID 21276848 DOI: 10.1016/j.bbi.2011.01.012  0.725
2011 Grace PM, Hutchinson MR, Bishop A, Somogyi AA, Mayrhofer G, Rolan PE. Adoptive transfer of peripheral immune cells potentiates allodynia in a graded chronic constriction injury model of neuropathic pain. Brain, Behavior, and Immunity. 25: 503-13. PMID 21134441 DOI: 10.1016/J.Bbi.2010.11.018  0.758
2011 Hay JL, La Vincente SF, Somogyi AA, Chapleo CB, White JM. Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects. European Journal of Pain (London, England). 15: 293-8. PMID 20728384 DOI: 10.1016/j.ejpain.2010.07.009  0.362
2011 Hutchinson M, Wu Y, Jaehne E, Liu L, Diener K, Hayball J, Rice K, Watkins L, Somogyi A. 97. Contributions of innate immune signaling to opioid & alcohol responses Brain, Behavior, and Immunity. 25: S206-S207. DOI: 10.1016/J.Bbi.2011.07.100  0.75
2011 Coller J, Hutchinson M, Daly A, White J, Somogyi A. 81. Association between immune genetic markers and alcohol dependence Brain, Behavior, and Immunity. 25: S202. DOI: 10.1016/j.bbi.2011.07.084  0.686
2010 Grace PM, Hutchinson MR, Manavis J, Somogyi AA, Rolan PE. A novel animal model of graded neuropathic pain: utility to investigate mechanisms of population heterogeneity. Journal of Neuroscience Methods. 193: 47-53. PMID 20817038 DOI: 10.1016/J.Jneumeth.2010.08.025  0.756
2010 Hutchinson MR, Lewis SS, Coats BD, Rezvani N, Zhang Y, Wieseler JL, Somogyi AA, Yin H, Maier SF, Rice KC, Watkins LR. Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences. Neuroscience. 167: 880-93. PMID 20178837 DOI: 10.1016/J.Neuroscience.2010.02.011  0.768
2010 Hutchinson MR, Chan S, Fong S, Phipps S, Somogyi AA, Yin H, Rice KC, Watkins LR. Novel Toll Like Receptor 4 activity of opioids alters opioid response F1000research. 1. DOI: 10.7490/F1000Research.56.1  0.374
2010 Somogyi A, Hutchinson M, Liu L, Coller J. 107 PROINFLAMMATORY CYTOKINE GENETICS IN THE DEVELOPMENT OF PERIPHERAL NEUROPATHY AND POTENTIAL TREATMENT STRATEGIES European Journal of Pain Supplements. 4: 32-32. DOI: 10.1016/S1754-3207(10)70112-7  0.671
2010 Coller J, Wu Y, White J, Hutchinson M, Somogyi A. TLR4 haplotypes in alcohol and opioid dependent populations Brain, Behavior, and Immunity. 24: S25. DOI: 10.1016/j.bbi.2010.07.082  0.717
2010 Hutchinson M, Wu Y, Liu L, Phipps S, Rice K, Coller J, Watkins L, Somogyi A. Opioid and alcohol action: The role of brain and spinal cord innate immune signalling Brain, Behavior, and Immunity. 24: S19. DOI: 10.1016/J.Bbi.2010.07.060  0.74
2009 Coller JK, Beardsley J, Bignold J, Li Y, Merg F, Sullivan T, Cox TC, Somogyi AA. Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid dependence: A meta-analysis. Pharmacogenomics and Personalized Medicine. 2: 9-19. PMID 23226031 DOI: 10.2147/Pgpm.S4865  0.369
2009 Liu L, Hutchinson MR, White JM, Somogyi AA, Coller JK. Association of IL-1B genetic polymorphisms with an increased risk of opioid and alcohol dependence. Pharmacogenetics and Genomics. 19: 869-76. PMID 19801958 DOI: 10.1097/FPC.0b013e328331e68f  0.706
2009 Hallinan R, Crettol S, Agho K, Attia J, Besson J, Croquette-Krokar M, Hämmig R, Déglon JJ, Byrne A, Ray J, Somogyi AA, Eap CB. Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study. European Journal of Clinical Pharmacology. 65: 1113-20. PMID 19639308 DOI: 10.1007/s00228-009-0706-8  0.33
2009 Bell J, Shearer J, Ryan A, Graham R, Korompay K, Rizzo S, Sindhusake D, Somogyi AA. The acceptability, safety, and tolerability of methadone/naloxone in a 50:1 ratio. Experimental and Clinical Psychopharmacology. 17: 146-53. PMID 19586229 DOI: 10.1037/a0016302  0.375
2009 Hay JL, White JM, Bochner F, Somogyi AA, Semple TJ, Rounsefell B. Hyperalgesia in opioid-managed chronic pain and opioid-dependent patients. The Journal of Pain : Official Journal of the American Pain Society. 10: 316-22. PMID 19101210 DOI: 10.1016/j.jpain.2008.10.003  0.387
2009 Coller JK, Christrup LL, Somogyi AA. Role of active metabolites in the use of opioids. European Journal of Clinical Pharmacology. 65: 121-39. PMID 18958460 DOI: 10.1007/s00228-008-0570-y  0.405
2008 Somogyi AA, Larsen M, Abadi RM, Jittiwutikarn J, Ali R, White JM. Flexible dosing of tincture of opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics. British Journal of Clinical Pharmacology. 66: 640-7. PMID 19032172 DOI: 10.1111/j.1365-2125.2008.03277.x  0.391
2008 Hutchinson MR, Coats BD, Lewis SS, Zhang Y, Sprunger DB, Rezvani N, Baker EM, Jekich BM, Wieseler JL, Somogyi AA, Martin D, Poole S, Judd CM, Maier SF, Watkins LR. Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain, Behavior, and Immunity. 22: 1178-89. PMID 18599265 DOI: 10.1016/J.Bbi.2008.05.004  0.764
2008 Hay JL, White JM, Bochner F, Somogyi AA. Antinociceptive effects of high-dose remifentanil in male methadone-maintained patients. European Journal of Pain (London, England). 12: 926-33. PMID 18262451 DOI: 10.1016/j.ejpain.2007.12.012  0.402
2008 Davies BJ, Herbert MK, Coller JK, Somogyi AA, Milne RW, Sallustio BC. Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. British Journal of Clinical Pharmacology. 65: 347-54. PMID 17875193 DOI: 10.1111/j.1365-2125.2007.03015.x  0.32
2008 La Vincente SF, White JM, Somogyi AA, Bochner F, Chapleo CB. Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects. Clinical Pharmacology and Therapeutics. 83: 144-52. PMID 17568402 DOI: 10.1038/sj.clpt.6100262  0.375
2007 Inglis SC, Herbert MK, Davies BJ, Coller JK, James HM, Horowitz JD, Morris RG, Milne RW, Somogyi AA, Sallustio BC. Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia. Pharmacogenetics and Genomics. 17: 305-12. PMID 17429312 DOI: 10.1097/FPC.0b013e32800ffba0  0.311
2007 Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clinical Pharmacology and Therapeutics. 81: 429-44. PMID 17339873 DOI: 10.1038/sj.clpt.6100095  0.421
2006 Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clinical Pharmacology and Therapeutics. 80: 682-90. PMID 17178268 DOI: 10.1016/j.clpt.2006.09.011  0.379
2006 Villesen HH, Foster DJ, Upton RN, Christrup LL, Somogyi AA, Martinez A, Grant C. Blood-brain distribution of morphine-6-glucuronide in sheep. British Journal of Pharmacology. 149: 754-60. PMID 17016501 DOI: 10.1038/sj.bjp.0706916  0.318
2006 Mitchell TB, White JM, Somogyi AA, Bochner F. Switching between methadone and morphine for maintenance treatment of opioid dependence: impact on pain sensitivity and mood status. The American Journal On Addictions / American Academy of Psychiatrists in Alcoholism and Addictions. 15: 311-5. PMID 16867927 DOI: 10.1080/10550490600754374  0.39
2006 Davies BJ, Herbert MK, Coller JK, Somogyi AA, Milne RW, Sallustio BC. Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 843: 302-9. PMID 16837252 DOI: 10.1016/j.jchromb.2006.06.020  0.304
2006 Mitchell TB, Dyer KR, Newcombe D, Somogyi AA, White JM. Fluctuations in (R,S)-methadone pharmacokinetics and response among long-term methadone maintenance patients. Addiction Biology. 11: 170-4. PMID 16800831 DOI: 10.1111/j.1369-1600.2006.00014.x  0.309
2006 Villesen HH, Foster DJ, Upton RN, Somogyi AA, Martinez A, Grant C. Cerebral kinetics of oxycodone in conscious sheep. Journal of Pharmaceutical Sciences. 95: 1666-76. PMID 16729270 DOI: 10.1002/jps.20632  0.313
2006 Barratt DT, Coller JK, Somogyi AA. Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 141: 323-31. PMID 16583408 DOI: 10.1002/ajmg.b.30319  0.359
2006 Morrish GA, Foster DJ, Somogyi AA. Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids. British Journal of Clinical Pharmacology. 61: 326-35. PMID 16487227 DOI: 10.1111/j.1365-2125.2005.02573.x  0.336
2006 Davies BJ, Coller JK, James HM, Somogyi AA, Horowitz JD, Sallustio BC. The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia. British Journal of Clinical Pharmacology. 61: 321-5. PMID 16487226 DOI: 10.1111/j.1365-2125.2005.02570.x  0.309
2006 Athanasos P, Smith CS, White JM, Somogyi AA, Bochner F, Ling W. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations. Pain. 120: 267-75. PMID 16427197 DOI: 10.1016/j.pain.2005.11.005  0.413
2005 Hutchinson MR, Somogyi AA. Characterisation of the in vitro modulation of splenocyte proliferation by non-4,5-epoxymorphinan opioids. International Immunopharmacology. 5: 1713-22. PMID 16102521 DOI: 10.1016/j.intimp.2005.05.006  0.733
2004 Somogyi AA, Menelaou A, Fullston SV. CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 34: 875-87. PMID 15764408 DOI: 10.1080/00498250400008371  0.32
2004 Mitchell TB, Dyer KR, Newcombe D, Salter A, Somogyi AA, Bochner F, White JM. Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure. British Journal of Clinical Pharmacology. 58: 609-17. PMID 15563359 DOI: 10.1111/j.1365-2125.2004.02221.x  0.321
2004 Jittiwutikarn J, Ali R, White JM, Bochner F, Somogyi AA, Foster DJ. Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre. British Journal of Clinical Pharmacology. 58: 536-41. PMID 15521902 DOI: 10.1111/j.1365-2125.2004.02209.x  0.408
2004 Newcombe DA, Bochner F, White JM, Somogyi AA. Evaluation of levo-alpha-acetylmethdol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal: a pharmacokinetic and pharmacodynamic analysis. Drug and Alcohol Dependence. 76: 63-72. PMID 15380290 DOI: 10.1016/j.drugalcdep.2004.04.004  0.353
2004 Hutchinson MR, Somogyi AA. (S)-(+)-methadone is more immunosuppressive than the potent analgesic (R)-(--)-methadone. International Immunopharmacology. 4: 1525-30. PMID 15351321 DOI: 10.1016/j.intimp.2004.07.011  0.735
2004 Hutchinson MR, La Vincente SF, Somogyi AA. In vitro opioid induced proliferation of peripheral blood immune cells correlates with in vivo cold pressor pain tolerance in humans: a biological marker of pain tolerance. Pain. 110: 751-5. PMID 15288416 DOI: 10.1016/j.pain.2004.05.017  0.738
2004 Mitchell TB, White JM, Somogyi AA, Bochner F. Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction (Abingdon, England). 99: 940-5. PMID 15265090 DOI: 10.1111/j.1360-0443.2004.00764.x  0.359
2004 Hutchinson MR, Somogyi AA. Relationship between 4,5-epoxymorphinan structure and in vitro modulation of cell proliferation. European Journal of Pharmacology. 494: 251-62. PMID 15212982 DOI: 10.1016/j.ejphar.2004.04.049  0.728
2004 Foster DJ, Somogyi AA, White JM, Bochner F. Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. British Journal of Clinical Pharmacology. 57: 742-55. PMID 15151520 DOI: 10.1111/j.1365-2125.2004.02079.x  0.338
2004 Davies BJ, Coller JK, James HM, Gillis D, Somogyi AA, Horowitz JD, Morris RG, Sallustio BC. Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline. British Journal of Clinical Pharmacology. 57: 456-63. PMID 15025744 DOI: 10.1046/j.1365-2125.2003.02033.x  0.3
2004 Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. British Journal of Clinical Pharmacology. 57: 287-97. PMID 14998425 DOI: 10.1046/j.1365-2125.2003.02002.x  0.688
2004 Athanasos P, Morrish G, Somogyi AA, Bochner F, White JM. Changes in Methadone Concentration, Opioid Effects, and Opioid Withdrawal During Induction Onto Maintenance Treatment Addictive Disorders & Their Treatment. 3: 122-128. DOI: 10.1097/01.adt.0000129086.89345.a9  0.373
2003 Mitchell TB, White JM, Somogyi AA, Bochner F. Comparative pharmacodynamics and pharmacokinetics of methadone and slow-release oral morphine for maintenance treatment of opioid dependence. Drug and Alcohol Dependence. 72: 85-94. PMID 14563546 DOI: 10.1016/S0376-8716(03)00190-X  0.416
2003 Menelaou A, Hutchinson MR, Quinn I, Christensen A, Somogyi AA. Quantification of the O- and N-demethylated metabolites of hydrocodone and oxycodone in human liver microsomes using liquid chromatography with ultraviolet absorbance detection. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 785: 81-8. PMID 12535841 DOI: 10.1016/S1570-0232(02)00856-5  0.677
2002 Hutchinson MR, Somogyi AA. Diacetylmorphine degradation to 6-monoacetylmorphine and morphine in cell culture: implications for in vitro studies. European Journal of Pharmacology. 453: 27-32. PMID 12393056 DOI: 10.1016/S0014-2999(02)02365-8  0.698
2002 Porter SJ, Somogyi AA, White JM. In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. Addiction Biology. 7: 219-25. PMID 12006217 DOI: 10.1080/135562102200120442  0.332
2001 Chew M, White JM, Somogyi AA, Bochner F, Irvine RJ. Precipitated withdrawal following codeine administration is dependent on CYP genotype. European Journal of Pharmacology. 425: 159-64. PMID 11513833 DOI: 10.1016/S0014-2999(01)01185-2  0.377
2001 Doverty M, Somogyi AA, White JM, Bochner F, Beare CH, Menelaou A, Ling W. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain. 93: 155-63. PMID 11427327 DOI: 10.1016/S0304-3959(01)00306-2  0.407
2001 Dyer KR, White JM, Foster DJ, Bochner F, Menelaou A, Somogyi AA. The relationship between mood state and plasma methadone concentration in maintenance patients. Journal of Clinical Psychopharmacology. 21: 78-84. PMID 11199952 DOI: 10.1097/00004714-200102000-00014  0.316
2001 Doverty M, White JM, Somogyi AA, Bochner F, Ali R, Ling W. Hyperalgesic responses in methadone maintenance patients. Pain. 90: 91-6. PMID 11166974 DOI: 10.1016/S0304-3959(00)00391-2  0.327
2000 Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. British Journal of Clinical Pharmacology. 50: 427-40. PMID 11069437 DOI: 10.1046/J.1365-2125.2000.00272.X  0.344
1999 Dyer KR, Foster DJ, White JM, Somogyi AA, Menelaou A, Bochner F. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clinical Pharmacology and Therapeutics. 65: 685-94. PMID 10391674 DOI: 10.1016/S0009-9236(99)90090-5  0.374
1999 Bochner F, Somogyi A, Christrup L, Larsen U, Danz C, Elb??k K. Comparative Pharmacokinetics of Two Modified-Release Oral Morphine Formulations (Reliadol?? and Kapanol??) and an Immediate-Release Morphine Tablet (Morfin ???DAK???) in Healthy Volunteers Clinical Drug Investigation. 17: 59-66. DOI: 10.2165/00044011-199917010-00007  0.345
1998 Wood MM, Ashby MA, Somogyi AA, Fleming BG. Neuropsychological and pharmacokinetic assessment of hospice inpatients receiving morphine. Journal of Pain and Symptom Management. 16: 112-20. PMID 9737102 DOI: 10.1016/S0885-3924(98)00043-8  0.357
1997 Ashby M, Fleming B, Wood M, Somogyi A. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. Journal of Pain and Symptom Management. 14: 157-67. PMID 9291702 DOI: 10.1016/S0885-3924(97)00020-1  0.372
1997 Van Crugten JT, Somogyi AA, Nation RL, Reynolds G. The effect of old age on the disposition and antinociceptive response of morphine and morphine-6 beta-glucuronide in the rat. Pain. 71: 199-205. PMID 9211481 DOI: 10.1016/S0304-3959(97)03363-0  0.352
1997 van Crugten JT, Somogyi AA, Nation RL, Reynolds G. Concentration-effect relationships of morphine and morphine-6 beta-glucuronide in the rat. Clinical and Experimental Pharmacology & Physiology. 24: 359-64. PMID 9143788 DOI: 10.1111/J.1440-1681.1997.Tb01202.X  0.372
1996 Milne RW, Nation RL, Somogyi AA. The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metabolism Reviews. 28: 345-472. PMID 8875123 DOI: 10.3109/03602539608994011  0.355
1996 Somogyi AA, Reinhard HA, Bochner F. Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. British Journal of Clinical Pharmacology. 41: 175-9. PMID 8866915 DOI: 10.1111/J.1365-2125.1996.Tb00179.X  0.323
1996 Somogyi AA, Reinhard HA, Bochner F. Effects of omeprazole and cimetidine on the urinary metabolic ratio of proguanil in healthy volunteers. European Journal of Clinical Pharmacology. 50: 417-9. PMID 8839666 DOI: 10.1007/S002280050133  0.31
1996 Maddocks I, Somogyi A, Abbott F, Hayball P, Parker D. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone Journal of Pain and Symptom Management. 12: 182-189. PMID 8803381 DOI: 10.1016/0885-3924(96)00050-4  0.378
1993 Somogyi AA, Nation RL, Olweny C, Tsirgiotis P, van Crugten J, Milne RW, Cleary JF, Danz C, Bochner F. Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine. Clinical Pharmacokinetics. 24: 413-20. PMID 8504624 DOI: 10.2165/00003088-199324050-00005  0.382
1992 Somogyi A, Bochner F, Chen ZR. Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man. European Journal of Clinical Pharmacology. 41: 379-82. PMID 1804656 DOI: 10.1007/BF00314972  0.368
1992 Milne RW, Nation RL, Somogyi AA, Bochner F, Griggs WM. The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients. British Journal of Clinical Pharmacology. 34: 53-9. PMID 1633068 DOI: 10.1111/J.1365-2125.1992.Tb04107.X  0.354
1991 Chen ZR, Somogyi AA, Reynolds G, Bochner F. Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. British Journal of Clinical Pharmacology. 31: 381-90. PMID 2049245 DOI: 10.1111/J.1365-2125.1991.Tb05550.X  0.357
1991 Mikus G, Somogyi AA, Bochner F, Eichelbaum M. Codeine O-demethylation: rat strain differences and the effects of inhibitors. Biochemical Pharmacology. 41: 757-62. PMID 1998530 DOI: 10.1016/0006-2952(91)90077-I  0.304
1991 Sloan PA, Mather LE, McLean CF, Rutten AJ, Nation RL, Milne RW, Runciman WB, Somogyi AA. Physiological disposition of i.v. morphine in sheep. British Journal of Anaesthesia. 67: 378-86. PMID 1931393 DOI: 10.1093/bja/67.4.378  0.384
1991 Milne RW, Nation RL, Reynolds GD, Somogyi AA, Van Crugten JT. High-performance liquid chromatographic determination of morphine and its 3- and 6-glucuronide metabolites: improvements to the method and application to stability studies. Journal of Chromatography. 565: 457-64. PMID 1874894 DOI: 10.1016/0378-4347(91)80410-E  0.334
1991 Chen ZR, Irvine RJ, Somogyi AA, Bochner F. Mu receptor binding of some commonly used opioids and their metabolites. Life Sciences. 48: 2165-71. PMID 1851921 DOI: 10.1016/0024-3205(91)90150-A  0.349
1990 Chen ZR, Irvine RJ, Bochner F, Somogyi AA. Morphine formation from codeine in rat brain: a possible mechanism of codeine analgesia. Life Sciences. 46: 1067-74. PMID 2333013 DOI: 10.1016/0024-3205(90)90415-N  0.304
1990 Somogyi A, Hewson D, Muirhead M, Bochner F. Amiloride disposition in geriatric patients: importance of renal function. British Journal of Clinical Pharmacology. 29: 1-8. PMID 2297454 DOI: 10.1111/J.1365-2125.1990.TB03595.X  0.305
1990 Evans AM, Nation RL, Sansom LN, Bochner F, Somogyi AA. The relationship between the pharmacokinetics of ibuprofen enantiomers and the dose of racemic ibuprofen in humans. Biopharmaceutics & Drug Disposition. 11: 507-18. PMID 2207301 DOI: 10.1002/Bdd.2510110605  0.306
1990 Somogyi A, Nation R, Olweny C, Cleary J, Tsirgiotis P, Milne R, van Crugten C, Bochner F. Plasma concentrations and renal clearances of morphine-6- and morphine-3-glucuronide in cancer patients receiving morphine Pain. 41: S193. DOI: 10.1016/0304-3959(90)92523-S  0.365
1990 Chen ZR, Ritchie R, Irvine RJ, Bochner F, Somogyi A. Plasma morphine concentration-analgesic relationship in the rat after codeine and morphine Pain. 41. DOI: 10.1016/0304-3959(90)92522-R  0.357
1990 Sloan P, Mather L, McLean C, Rutten A, Nation R, Milne R, Runciman W, Somogyi A. The physiological disposition of morphine in sheep Pain. 41: S190. DOI: 10.1016/0304-3959(90)92517-T  0.352
1988 Somogyi AA, Bochner F. The absorption and disposition of enoxacin in healthy subjects. Journal of Clinical Pharmacology. 28: 707-13. PMID 3216037 DOI: 10.1002/J.1552-4604.1988.Tb03204.X  0.315
1988 Chen ZR, Bochner F, Somogyi A. Pharmacokinetics of pholcodine in healthy volunteers: single and chronic dosing studies. British Journal of Clinical Pharmacology. 26: 445-53. PMID 3190994 DOI: 10.1111/J.1365-2125.1988.TB03404.X  0.324
1987 Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man British Journal of Clinical Pharmacology. 23: 545-551. PMID 3593625 DOI: 10.1111/J.1365-2125.1987.Tb03090.X  0.586
1987 Somogyi AA, Bochner F, Keal JA, Rolan PE, Smith M. Effect of food on enoxacin absorption. Antimicrobial Agents and Chemotherapy. 31: 638-9. PMID 3475034 DOI: 10.1128/Aac.31.4.638  0.575
1986 Stockley C, Keal J, Rolan P, Bochner F, Somogyi A. Lack of inhibition of tolbutamide hydroxylation by cimetidine in man European Journal of Clinical Pharmacology. 31: 235-237. PMID 3803421 DOI: 10.1007/Bf00606666  0.591
1986 Muirhead MR, Somogyi AA, Rolan PE, Bochner F. Effect of cimetidine on renal and hepatic drug elimination: studies with triamterene. Clinical Pharmacology and Therapeutics. 40: 400-7. PMID 3757403 DOI: 10.1038/Clpt.1986.197  0.608
1986 Somogyi A, Rolan P. Drug disposition and dosing in hepatic disease. The Medical Journal of Australia. 145: 284-289. PMID 3747914 DOI: 10.5694/J.1326-5377.1986.Tb101126.X  0.565
1986 Rolan P, Somogyi A. Prescribing for the patient with renal disease. The Medical Journal of Australia. 145: 210-215. PMID 2875383 DOI: 10.5694/J.1326-5377.1986.Tb113814.X  0.548
1984 Eichelbaum M, Somogyi A. Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil. European Journal of Clinical Pharmacology. 26: 47-53. PMID 6714292 DOI: 10.1007/Bf00546708  0.316
1984 Somogyi AA, Kong CB, Gurr FW, Sabto J, Spicer WJ, McLean AJ. Metronidazole pharmacokinetics in patients with acute renal failure. The Journal of Antimicrobial Chemotherapy. 13: 183-9. PMID 6706889 DOI: 10.1093/Jac/13.2.183  0.304
1984 Somogyi A, Gugler R. Clinical pharmacokinetics of cimetidine. Clinical Pharmacokinetics. 8: 463-95. PMID 6418428 DOI: 10.2165/00003088-198308060-00001  0.321
1984 Somogyi A, Bochner F. Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. British Journal of Clinical Pharmacology. 18: 175-81. PMID 6091709 DOI: 10.1111/J.1365-2125.1984.TB02450.X  0.318
1983 Rolan PE, Somogyi AA, Drew MJ, Cobain WG, South D, Bochner F. Phenytoin intoxication during treatment with parenteral miconazole. British Medical Journal (Clinical Research Ed.). 287: 1760. PMID 6416579 DOI: 10.1136/Bmj.287.6407.1760  0.547
1981 Gugler R, Brand M, Somogyi A. Impaired cimetidine absorption due to antacids and metoclopramide. European Journal of Clinical Pharmacology. 20: 225-228. PMID 7286040 DOI: 10.1007/Bf00544602  0.305
1981 Somogyi A, Albrecht M, Kliems G, Schafer K, Eichelbaum M. Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. British Journal of Clinical Pharmacology. 12: 51-60. PMID 7248141 DOI: 10.1111/J.1365-2125.1981.Tb01854.X  0.315
1981 Somogyi A, Thielscher S, Gugler R. Influence of phenobarbital treatment on cimetidine kinetics. European Journal of Clinical Pharmacology. 19: 343-347. PMID 7238562 DOI: 10.1007/Bf00544584  0.319
1980 Eichelbaum M, Birkel P, Grube E, Gütgemann U, Somogyi A. Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single i.v. and oral administration and during chronic treatment Journal of Molecular Medicine. 58: 919-925. PMID 7206587 DOI: 10.1007/Bf01477049  0.306
1979 Shanks CA, Somogyi AA, Triggs EJ. Dose-response and plasma concentration-response relationships of pancuronium in man. Anesthesiology. 51: 111-8. PMID 453610 DOI: 10.1097/00000542-197908000-00004  0.302
1976 Somogyi AA, Shanks CA, Triggs EJ. Clinical pharmacokinetics of pancuronium bromide. European Journal of Clinical Pharmacology. 10: 367-72. PMID 789085 DOI: 10.1007/Bf00565627  0.303
Show low-probability matches.